Dasatinib 70 mg 60 tabs LUCIUS India
Sprycel generic analogue, dasatinib
Indications:
Chronic myeloid leukemia (CML) in the accelerated or blast phase with resistance or intolerance to previous therapy, which included imatinib mesylate.
Acute lymphoblastic leukemia with a positive Philadelphia chromosome (Ph + ALL), as well as the lymphoblastic form of chronic myeloid leukemia (CML) with resistance or intolerance to previous therapy.
Dosage and administration:
Apply to adults. Treatment should be carried out by a physician experienced in the diagnosis and treatment of patients with leukemia.
The initial dose for CML in the chronic phase is 100 mg once a day, orally in the morning or evening.
The initial dose for CML in the accelerated phase in myeloblastic or lymphoblastic crisis and in patients with Ph + ALL is recommended 140 mg per day (70 mg orally in the morning and evening).
Tablets are taken regardless of food intake, swallowed whole, without breaking. The required dose is formed by a combination of 20 mg, 50 mg, 70 mg tablets. Increasing or decreasing the dose is due to the sensitivity or tolerance of the patient to therapy. In severe manifestations of CML or Ph + ALL, the dose may be increased to 100 mg 2 times a day.
-
Commercial name:Dasatinib
-
Dosage:50 mg
-
Quantity:60
-
Release form:Tablets
-
Виробник:Индия